Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.

@article{Moreira2018LiraglutideMG,
  title={Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.},
  author={Geane Moreira and Fl{\'a}via Figueiredo Azevedo and Larissa Mayume Ribeiro and Andr{\'e}ia Montesdioca dos Santos and Dioze Guadagnini and Patr{\'i}cia Gama and Edson Aparecido Liberti and Mja Saad and Carla R O Carvalho},
  journal={The Journal of nutritional biochemistry},
  year={2018},
  volume={62},
  pages={
          143-154
        }
}
Metabolic disorders such as insulin resistance and diabetes are associated with obesity and nonalcoholic fatty liver disease (NAFLD). The aggressive form of a fatty liver disease may progress to cirrhosis and hepatocellular carcinoma. Furthermore, recent studies demonstrated that there is a dysbiosis in the gut microbiota associated with early stages of metabolic disease. Therefore, the identification and repurposing of drugs already used to treat insulin resistance may be an excellent option… CONTINUE READING
BETA
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Similar Papers

Loading similar papers…